CPa9-HNE™ is the serum calprotectin biomarker that measures true neutrophil activity by detecting a specific calprotectin fragment. Unlike full-length calprotectin, CPa9-HNE is released only during active inflammation, making it a valuable tool for assessing immune response and monitoring treatment effects in conditions like IBD. Supported by an FDA Letter of Support, it has potential for improving clinical trials by enabling non-invasive assessment of disease activity.

Crohn’s disease involves complex immune activation, tissue damage, and fibrosis that are not always captured by traditional assessments. The Nordic IBDTrace™ biomarker panel offers a non-invasive, blood-based solution to monitor mucosal damage, immune activity, and extracellular matrix remodeling. These biomarkers support patient stratification, treatment monitoring, and trial optimization, helping refine drug development and therapeutic strategies.

Intestinal fibrosis is a common complication of chronic IBD, particularly in Crohn’s disease, where it can lead to strictures and non-response to therapy. The Nordic IBDTrace™ biomarker panel offers non-invasive tools to assess fibroblast activity, monitor fibrosis progression, and support antifibrotic drug development. These biomarkers aid in patient stratification and therapeutic evaluation in both clinical practice and trials.

Esophageal fibrosis in eosinophilic esophagitis (EoE) results from excess collagen deposition and structural remodeling of the tissue. Nordic Bioscience’s biomarkers offer non-invasive insight into extracellular matrix turnover, helping assess fibrosis severity, monitor disease progression, and evaluate treatment response. These tools support biomarker-driven strategies for clinical development and patient stratification in EoE.